| Literature DB >> 32183759 |
Onesmus Kamacooko1, Yunia Mayanja2, Daniel Bagiire2, Gertrude Namale2, Christian Holm Hansen2,3, Janet Seeley2,3.
Abstract
BACKGROUND: Immediate uptake of antiretroviral therapy (ART) after an HIV-positive diagnosis (Test and Treat) is now being implemented in Uganda. Data are limited on lost to follow-up (LTFU) in high-risk cohorts that have initiated 'Test and Treat'. We describe LTFU in a cohort of women of high-risk sexual behaviour who initiated ART under "Test and Treat".Entities:
Keywords: Loss to follow-up; sub-Saharan Africa; Lost to follow-up; Universal test and treat; Women at high-risk
Mesh:
Substances:
Year: 2020 PMID: 32183759 PMCID: PMC7079529 DOI: 10.1186/s12889-020-8439-9
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Screening Profile of Study Participants
Baseline sociodemographic and clinical characteristics of the 293 study participants enrolled in the Test and Treat programme between August 2014 and March 2018 in Kampala Uganda
| Characteristics | Category | Frequency | Did not start ART at GHWP | Chi-Square |
|---|---|---|---|---|
| Mean age (SD) | 30.3 (6.5) | 28.4 (6.1) | < 0.001 | |
| Age at enrolment (year) | < 25 | 50 (17.1) | 178 (30) | < 0.001 |
| 25–34 | 175 (59.7) | 303 (52) | ||
| 35+ | 68 (23.2) | 107 (18) | ||
| Marital Status | Widowed/Separated | 196 (66.9) | 425 (72) | < 0.001 |
| Married | 45 (15.4) | 36 (6) | ||
| Never married | 52 (17.7) | 127 (22) | ||
| Current job | No sex work | 96 (32.8) | 136 (23) | 0.002 |
| Sex worker | 197 (67.2) | 452 (77) | ||
| Highest formal education level attained | No education | 37 (12.6) | 60 (10) | 0.553 |
| Attended Primary school | 177 (60.4) | 363 (62) | ||
| Secondary school or higher | 79 (27.0) | 165 (28) | ||
| Alcohol Consumption Patterns (AUDIT score)a | Low risk | 113 (38.6) | ||
| High risk | 119 (40.6) | |||
| Dependent | 61 (20.8) | |||
| Reported paid sex | Yes | 274 (93.5) | 575 (98) | 0.001 |
| No | 19 (6.5) | 13 (2) | ||
| Year of ART starta | 2014 | 15 (5.1) | ||
| 2015 | 75 (25.6) | |||
| 2016 | 130 (44.4) | |||
| 2017 | 73 (24.9) | |||
| Baseline WHO stagea | WHO Stage I | 191 (65.2) | ||
| WHO Stage II | 75 (25.6) | |||
| WHO Stage III & IV | 27 (9.2) | |||
| Median CD4 count (IQR) | 530 (348,757) | |||
| Baseline CD4 count (cells/μl)a Median (IQR) | 0–350 | 74 (25.3) | ||
| Above 350 | 219 (74.7) | |||
| Ever tested for HIV before enrolling at the clinic | Yes | 255 (87) | 560 (95) | < 0.001 |
| No | 38 (13) | 28 (5) | ||
SD Standard deviation, IQR Interquartile range; AUDIT Scores: 0–7 Low Risk, 8–19 High risk, ≥20 Dependent; aNo available data for the comparison group
Fig. 2Kaplan-Meier plot showing LTFU of participants during the follow-up period
Multivariable analysis of predictors of Lost to follow-up among study participants enrolled in the Test and Treat programme between August 2014 and March 2018 in Kampala Uganda
*significant at P < 0.05; HR Hazard Ratio, I Confidence Interval, LRT Likelihood Ratio Test, LTR Estimated LTFU rate per 100 person-years, uHR Unadjusted Hazard Ratio, aHR Adjusted Hazard Ratio, Wald Wald Chi-square P-value; global test chi-square value = 6.90 and p-value = 0.548